Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21. PMID: 24449241.

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide Compared with Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated follow-up and Improved Survival

Antonio Palumbo, MD,[1] Sara Bringhen, MD,[1] Alessandra Larocca, MD,[1] Davide Rossi, MD,[2] Francesco Di Raimondo, MD,[3] Valeria Magarotto, MD,[1] Francesca Patriarca, MD,[4] Anna Levi, MD,[5] Giulia Benevolo, MD,[6] Iolanda Donatella Vincelli, MD,[7] Mariella Grasso, MD,[8] Luca Franceschini, MD,[9] Daniela Gottardi, MD,[10] Renato Zambello, MD,[11] Vittorio Montefusco, MD,[12] Antonietta Pia Falcone, MD,[13] Paola Omedé, Ph.D,[1] Roberto Marasca, MD,[14] Fortunato Morabito, MD,[15] Roberto Mina, MD,[1] Tommasina Guglielmelli, MD,[16] Chiara Nozzoli, MD,[17] Roberto Passera, Ph.D,[18] Gianluca Gaidano, MD,[2] Massimo Offidani, MD,[19] Roberto Ria, MD,[20] Maria Teresa Petrucci, MD,[5] Pellegrino Musto, MD,[21] Mario Boccadoro, MD,[1] Michele Cavo, MD[22]

[1]Myeloma Unit, Division of Hematology, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy; [2]Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; [3]Division of Hematologia, Ferrarotto Hospital, University of Catania, Catania, Italy; [4]Clinica Ematologica e Unità di Terapie Cellulari 'Carlo Melzi', Azienda Ospedaliera-Universitaria, Udine, Italy; [5]Department of Cellular Biotechnology and Haematology, Sapienza University of Rome, Italy; [6] S.C. Ematologia, A.O. Città della Salute e della Scienza di Torino, Torino, Italy; [7]Divison of Hematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy; [8]Department of Hematology, S. Croce e Carle Hospital, Cuneo, Italy; [9]Hematology, Tor Vergata University Hospital, Rome, Italy; [10]SCdU Ematologia e Terapie Cellulari - A.O. O. Mauriziano, Torino, Italy; [11]Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Padova, Padova, Italy; [12]Division of Hematology, IRCCS Istituto Nazionale dei Tumori Milano, University of Milano, Italy; [13]IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Unità di Ematologia, Italy; [14]Department of Medical Sciences, Section of Hematology, University of Modena, Italy; [15]UOC di Ematologia, Dipartimento Oncoematologico, AO di Cosenza, Italy; [16]Unit of Hematology, “S. Luigi Gonzaga” Hospital, Orbassano, Italy; [17]SODc Ematologia Azienda Ospedaliera Universitaria Careggi, Firenze, Italy; [18]Divison of Nuclear Medicine 2, San Giovanni Battista Hospital, University of Torino, Torino, Italy; [19]Division of Hematology, Ospedali Riuniti, Ancona, Italy; [20]University of Bari "Aldo Moro" Medical School Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology; Bari, Italy; [21]Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (Pz), Italy; [22]Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.

Running head: Improved survival with VMPT-VT versus VMP

Corresponding author:
Antonio Palumbo, Myeloma Unit, Division of Hematology, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy; tel.: +39 01 1663 5814; fax: +39 01 1696 3737; e-mail: appalumbo@yahoo.com

ABSTRACT

Purpose Bortezomib-melphalan-prednisone (VMP) has improved overall survival in multiple myeloma. This randomized trial compared bortezomib-melphalan-prednisone plus thalidomide induction, followed by bortezomib plus thalidomide maintenance (VMPT-VT) with VMP in patients with newly diagnosed multiple myeloma.

Methods We randomly assigned 511 patients, who were not eligible for transplantation, to receive VMPT-VT (nine 5-week cycles of VMPT followed by 2 years of VT maintenance) or VMP (nine 5-week cycles without maintenance). This study is registered at ClinicalTrials.gov, number, NCT01063179.

Results In the initial analysis, with a median follow-up of 23 months, VMPT-VT improved complete response rate from 24% to 38% and 3-year progression-free-survival from 41% to 56% compared with VMP. In the current analysis, median follow-up was 54 months. The median progression-free-survival was significantly longer with VMPT-VT (35.3 months) than with VMP (24.8 months; hazard ratio, 0.58; P<0.001). The time-to-next-therapy was 46.6 months in the VMPT-VT group and 27.8 months in the VMP group (hazard ratio 0.52; P<0.001). The 5-year overall survival was greater with VMPT-VT (61%) than with VMP (51%; hazard ratio, 0.70; P=0.01). Survival from relapse was identical in both groups (hazard ratio 0.92; P=0.63). In the VMPT-VT group the most frequent grade 3-4 adverse events included neutropenia (38%), thrombocytopenia (22%), peripheral neuropathy (11%) and cardiologic events (11%). All of these, except for thrombocytopenia, were significantly more frequent in the VMPT-VT patients.

Conclusion Bortezomib and thalidomide significantly improved overall survival in multiple myeloma patients not eligible for transplantation.

INTRODUCTION

Multiple myeloma accounts for approximately 13% of hematologic cancers. The median age at diagnosis is 70 years; 63% of patients are older than 65 years of age.[1,2] In the near future the frequency of myeloma is likely to increase as the population ages. The median overall survival of patients treated with melphalan-prednisone is approximately 32 months. Combination therapy with melphalan-prednisone plus either thalidomide or bortezomib (VMP) is now considered the standard of care for patients who are not eligible for transplantation.[3,4] A large meta-analysis showed that the addition of thalidomide to melphalan-prednisone increased median overall survival by 6.6 months.[3] In a randomized trial the combination VMP increased overall survival by 13.3 months as compared with melphalan-prednisone alone.[5]

In comparison with VMP, the four-drug combination bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide (VMPT-VT) improved complete response rate from 24% to 38% and 3-year progression-free-survival from 41% to 56%.[6] In a meta-analysis of 9 different randomized studies, thalidomide maintenance reduced the risk of progression by 35% (HR 0.65, 95% CI, 0.59-0.72) while lenalidomide by approximately 55% (HR 0.45, 95% CI, 37-54) as compared with placebo, the survival benefit was inconsistent or marginal with both drugs.[7] In a recent study, a median progression-free-survival of 39 months was reported with bortezomib-thalidomide maintenance.[8]

In this phase III, multicenter, randomized study we compared the four-drug combination VMPT followed by VT maintenance with VMP. We present an updated analysis of outcome after a median follow-up of 4 years.

METHODS

Patients

The details of this randomized (1:1) phase III study, conducted at 61 centers in Italy from May 2006 to January 2009, have been reported.[6] Briefly, patients with newly diagnosed myeloma, who were not candidates for high-dose therapy plus stem-cell transplantation because of age (≥ 65 years) or coexisting comorbidities, were eligible. The primary endpoint was progression-free survival; secondary endpoints included response rate, time to the first evidence of response, overall survival, and incidence of any grade 3 or higher adverse events. Subgroup analyses were planned for prognostic factors.

Experimental therapy consisted of induction with nine 6-week cycles of oral melphalan at a dose of 9 mg/m^2 on days 1 to 4; oral prednisone at a dose of 60 mg/m^2 on days 1 to 4; intravenous bortezomib at a dose of 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29, and 32 during cycles 1 to 4 and on days 1, 8, 22, and 29 during cycles 5 to 9; and thalidomide at a dose of 50 mg per day continuously. After the last bortezomib-melphalan-prednisone-thalidomide course, patients received continuous therapy with bortezomib at a dose of 1.3 mg/m^2 every 15 days and thalidomide at a dose of 50 mg per day for two years or until progression or relapse. Standard VMP therapy consisted of induction therapy with nine 6-week cycles of bortezomib, melphalan, and prednisone at the same doses previously described, and no planned continuous therapy was delivered. As a consequence of the safety interim analysis the protocol was amended to reduce the incidence of peripheral neuropathy. After the inclusion of the first 139 patients, both VMPT-VT and VMP induction schedules were changed to nine 5-week cycles and bortezomib dose was modified to 1.3 mg/m^2 on days 1, 8, 15, and 22 during cycles 1 to 9 (Supplementary Appendix Figure 1). The study was approved by the institutional review board at each of the participating centers. All patients gave written informed consent before entering the study, which was performed in accordance with the Declaration of Helsinki.

Assessment

Response and progression were assessed after each cycle during induction and then every 6-8 weeks until disease progression. After disease progression was confirmed, patients were followed every 90

days for documentation of subsequent treatment and survival status. Progression-free-survival was calculated from the time of randomization until the date of progression, relapse, death for any cause, or the date the patient was last known to be in remission. Time-to-next-therapy (post-hoc analysis) was calculated from the time of randomization until the date of subsequent myeloma therapy administered at progression or relapse, the date of death for progressive disease, or the date the patient was last known to be in remission. Overall survival was calculated from the time of randomization until the date of death for any cause or the date the patient was last known to be alive. Survival from relapse was calculated from the time of relapse until the date of death for any cause or the date the patient was last known to be alive. The response to treatment was defined using the International Uniform Response Criteria.[9] All adverse events were assessed at each visit and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 3.0).[10]

Statistical analysis

Update analysis were performed using data collected through October 15, 2012. All results were evaluated on an intention-to-treat basis as well as within subgroups defined according to baseline characteristics. For univariate analyses, the overall survival and progression-free survival curves were estimated by the Kaplan-Meier method and compared using the log-rank test.[11] The Cox proportional hazard model was used to estimate the hazard ratio values and the 95% Confidence Interval (CI).[12] The univariate analyses were performed for the following covariates: age at diagnosis (≥75 vs. <75 yrs), gender (male vs. female), chemotherapy regimen (VMPT vs. VMP), International Staging System score,[13] cytogenetic profile (high vs. standard risk) [high risk defined as the presence of a t(4;14), t(14,16) or 17p deletion]. The effect of the same covariates on overall survival and progression-free survival was finally assessed by the multivariate Cox model. Time to event was expressed as median with interquartile range (IQR) or 5-year Kaplan-Meier estimate. All reported p-values were two-sided, at the conventional 5% significance level. Data were analyzed as of November, 2012 by IBM SPSS 20.0.0, R 2.15.0 and SAS System for Windows V8. This study is registered at ClnicalTrials.gov, number NCT01063179.

Role of the funding source

The study was supported by the Italian Medicines Agency (AIFA). The Agency had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit this manuscript for publication.

RESULTS

A total of 511 patients were randomly assigned to receive VMPT-VT (254 patients) or VMP (257 patients) (Fig. 1). Baseline demographics and disease characteristics were previously reported,[6] and are summarized in the Supplementary Appendix Table 1. Baseline characteristics were well balanced between the two treatment arms, the median age was 71 years, and 27% of patients were older than 75 years of age.

The median follow-up on survivor patients was 54 months. Progression or death occurred in 155 patients (61%) in the VMPT-VT group and 206 (80%) in the VMP group. The median progression-free-survival was 35.3 months in the VMPT-VT group and 24.8 months in the VMP group (hazard ratio, 0.58; P<0.001; Fig. 2A). The median time-to-next-therapy was 46.6 months in the VMPT-VT group and 27.8 months in the VMP group (hazard ratio, 0.52; P<0.001; Fig. 2B). In the VMPT-VT group, the median time-to–next-therapy (symptomatic progression) was delayed by approximately 12 months in comparison with the median progression-free-survival (asymptomatic progression).

Death occurred in 82 patients (32%) in the VMPT-VT group and 111 (43%) in the VMP group. In the VMPT-VT group, 16 patients (6%) withdrew consent and no patient was lost to follow-up; in the VMP group, 17 patients (7%) withdrew consent and 8 patients (3%) were lost to follow-up (Fig.

1). VMPT-VT significantly prolonged overall survival (5-year overall survival 61%) as compared with VMP (5-year overall survival 51%; hazard ratio, 0.70; P=0.01; Fig. 2C).
In the VMPT-VT group, 10 patients (4%) received therapy at first relapse with bortezomib, 64 (25%) with thalidomide or lenalidomide, 29 (11%) with conventional chemotherapy, and 2 with radiotherapy (1%). In the VMP group, 28 patients (11%) received therapy at first relapse with bortezomib, 100 (39%) with thalidomide or lenalidomide, 22 (8%) with conventional chemotherapy, and 2 with radiotherapy (1%). In both groups, overall survival from relapse was similar (hazard ratio, 0.92; P=0.63; Fig. 2D).
In multivariate analysis (Supplementary Appendix Table 2), treatment with VMPT-VT (hazard ratio, 0.69, P=0.02), age < 75 years (hazard ratio, 0.58; P=0.002), female gender (hazard ratio, 0.62; P=0.003), and International Staging System stage I/II (hazard ratio, 0.69; P=0.04) were factors associated with significantly longer overall survival.
The most frequent adverse events were hematologic (Table 1). Grade 3 to 4 neutropenia was reported in 96 patients (38%) in the VMPT-VT group, and 71 patients (28%) in the VMP group; grade 3 to 4 thrombocytopenia occurred in 55 patients (22%) and 50 patients (20%), respectively. The most frequent and clinical relevant non-hematologic adverse events included infections (13% and 9%), cardiologic events (11% and 5%), peripheral neuropathy (11% and 5%), with VMPT-VT and VMP, respectively.
During the maintenance phase with VT, the incidence of new or worsened grade 3 to 4 adverse events was low (<5%). Grade 3 to 4 neutropenia was reported in 4 patients (3%), peripheral neuropathy in 6 patients (4%), and cardiologic adverse events in 2 patients (1%).
In the VMPT-VT group, 46 of the 186 patients younger than 75 years (25%) required treatment interruption for adverse events and received 81% of the planned dose intensity of bortezomib and 24 of the 68 patients older than 75 years (35%) discontinued treatment for adverse events and received 58% of the planned dose intensity. In the VMP group, 29 of the 188 patients younger than 75 years (15%) required treatment interruption for adverse events and received 89% of the planned dose intensity of bortezomib and 11 of the 69 patients older than 75 years (16%) discontinued treatment for adverse events and received 80% of the planned dose intensity (Table 3 in the Supplementary Appendix).

DISCUSSION

This randomized phase III study showed that VMPT-VT, a four-drug induction regimen followed by VT maintenance, was more effective than VMP. In patients with newly diagnosed multiple myeloma who are ineligible for transplantation, VMPT-VT improved progression-free-survival, time-to-next-therapy and overall survival by approximately 1 year. For the first time, the superiority of a new drug combination, VMPT-VT, over the standard of care VMP has been determined.
A large meta-analysis of 1685 individual patient data from 6 randomized studies showed a median overall survival of 32.7 months with melphalan-prednisone and 39.3 months with the addition of thalidomide to melphalan-prednisone.[3,14-20] In the VISTA study, the median overall survival was 56.4 months for patients who received VMP.[4,5] In our study, the median overall survival was 60.6 months with VMP and was 61% at 5 years with VMPT-VT. In younger transplant eligible patients, bortezomib as induction before autologous transplantation induced a 3-year overall survival rate of 81.4%.[21] Similarly, bortezomib as induction and as maintenance after autologous transplantation induced a 5-year overall survival of 61%.[22] The introduction of novel agents questioned the role of autologous transplantation for myeloma patients. Results from the ongoing prospective randomized studies are warranted to draw definitive conclusions.[23]

The achievement of complete response is associated with prolonged overall survival.[24-26] A retrospective analysis of 1175 elderly newly diagnosed multiple myeloma patients demonstrated that the achievement of complete response was an independent predictor of longer overall survival and supports the use of combinational approach to achieve maximal response in elderly patients.[26]

Maintenance therapy can improve outcome and its role has been extensively investigated. A meta-analysis of 2786 patients demonstrated that thalidomide maintenance reduced the risk of progression by 35% and the risk of death by 16% in both young and elderly patients.[7] A phase III trial showed that lenalidomide as induction and as maintenance reduced the risk of progression by 51% in comparison with lenalidomide as induction without maintenance.[27] A phase III study showed that bortezomib as induction and as maintenance reduced the risk of death by 23% in comparison with conventional induction and thalidomide maintenance.[22] In our trial, the 4-drug combination followed by maintenance significantly improved the complete response rate by 14%[6] and the 5-year overall survival by 10% compared with the 3-drug combination without maintenance.

The difference between median progression-free-survival and time-to-next-therapy was approximately one year in the VMPT-VT group and 3 months in the VMP group. We might speculate that the combination of profound tumor reduction and continuous treatment delayed the occurrence of symptomatic disease progression, prolonging the time from biochemical to clinical relapse, i.e. the time from asymptomatic to symptomatic disease,[9] with a significant clinical benefit. Survival from relapse was similar in both groups. A fixed 2-year duration of maintenance does not appear to select more resistant clones. By contrast, continuous treatment until disease progression might increase the risk of resistant relapse.[14-16,27] In our study, the 4-drug combination followed by maintenance improved overall survival. Inconsistent results have been reported with immunomodulatory drugs.[27-30] Whether the survival advantage was mainly related to the presence of the proteasome inhibitor or to the additive value of proteasome inhibitor plus thalidomide remains to be determined.

The multivariate analysis outlined that International Staging System stage I/II and age less than 75 years were independent predictors of longer survival. The intensified VMPT-VT schedule was more effective in good prognosis patients. In incurable diseases, such as multiple myeloma, dose intensification may exert the most pronounced clinical benefit in patients with the most sensitive tumor. These findings are also in line with recent data demonstrating that bortezomib was not able to completely overcome the adverse prognosis of high risk cytogenetic abnormalities.[31,32]

In the VMPT-VT patients older than 75 years of age, a higher frequency of treatment discontinuations was reported. With VMPT-VT, younger patients received 81% of the planned cumulative dose intensity of bortezomib while older patients received only 58% of the planned dose. Appropriate screening of concomitant cardiac, pulmonary, renal, hepatic and neurological functions should be recommended in all patients and specifically in those older than 75 years of age. Advanced age and unrecognized concomitant diseases have probably a significant role in treatment discontinuation in patients with cancer. The presence of concomitant diseases requires lower dose intensity to improve tolerability and optimize efficacy, and three – or even two – drug combinations should be preferred.[33,34]

During induction, the once-weekly schedule of bortezomib was adopted, instead of the conventional twice-weekly schedule. The once-weekly administration significantly reduced the incidence of peripheral neuropathy, from 16% to 3%, without negatively affecting both progression-free-survival and overall survival.[6,35] During maintenance, the twice-monthly schedule of bortezomib and thalidomide at 50 mg/day were very well tolerated, with a discontinuation rate of 13% only. In previous studies, maintenance with thalidomide at 100-400 mg/day determined a discontinuation rate of approximately 40%.[7] During maintenance, toxicities significantly limit long-term treatment. Effective continuous treatment should be associated with a very low discontinuation rate to translate into a significant clinical benefit.

It is necessary to consider the possible limitations of any trial. In our study, the absence of a second randomization after induction made the maintenance versus no maintenance comparison problematic. Nevertheless, the entire VMPT-VT approach clearly induced better progression-free survival and overall survival than VMP. Yet, it remains difficult to dissect whether this superiority should be mainly attributed to the use of a 4-drug combination induction or to the use of a

maintenance treatment. The absence of a prespecified salvage therapy is another limitation. However, treatments at relapse were quite homogeneous between the two groups, thus allowing to better isolate the efficacy of the first-line therapy.

In conclusion, VMPT-VT improves overall survival in comparison with the recently adopted, standard of care VMP. The benefit is mainly evident in patients 65 to 75 years of age. Our findings suggest that the addition of bortezomib and thalidomide to melphalan-prednisone induction and as maintenance therapy is a valuable front-line strategy for fit myeloma patients who are not eligible for transplantation. These data lay the basis for less toxic and more effective combinations of new generation immunomodulatory drugs and proteasome-inhibitors, such as bortezomib-lenalidomide-dexamethasone[36] and carfilzomib-lenalidomide-dexamethasone[37].

Contributors

Conception and design: Antonio Palumbo and Mario Boccadoro.

Coordination and revision of the study: Massimo Offidani, Roberto Ria, Maria T Petrucci, and Pellegrino Musto.

Collection and assembly of data: Sara Bringhen.

Manuscript writing: Antonio Palumbo and Sara Bringhen.

Statistical analysis: Roberto Passera.

Laboratory analyses: Paola Omedé.

Provision of study material or patients: Sara Bringhen, Alessandra Larocca, Davide Rossi, Francesco Di Raimondo, Valeria Magarotto, Francesca Patriarca, Anna Levi, Giulia Benevolo, I D Vincelli, Mariella Grasso, L Franceschini, Daniela Gottardi, Renato Zambello, Vittorio Montefusco, Antonietta Pia Falcone, Roberto Marasca, Fortunato Morabito, Roberto Mina, Tommasina Guglielmelli, Chiara Nozzoli, Gianluca Gaidano, Massimo Offidani, Roberto Ria, Pellegrino Musto, Maria Teresa Petrucci, and Michele Cavo.

Final approval of manuscript: Antonio Palumbo, Sara Bringhen, Alessandra Larocca, Davide Rossi, Francesco Di Raimondo, Valeria Magarotto, Francesca Patriarca, Anna Levi, Giulia Benevolo, Iolanda Donatella Vincelli, Mariella Grasso, Luca Franceschini, Daniela Gottardi, Renato Zambello, Vittorio Montefusco, Antonietta Pia Falcone, Paola Omedé, Roberto Marasca, Fortunato Morabito, Roberto Mina, Tommasina Guglielmelli, Chiara Nozzoli, Roberto Passera, Gianluca Gaidano, Massimo Offidani, Roberto Ria, Maria Teresa Petrucci, Pellegrino Musto, Mario Boccadoro, Michele Cavo, .

Conflict of interest statement

Employment or leadership position: None

Consultancy or advisory role: Antonio Palumbo, Amgen (C), Bristol-Myers Squibb (C), Celgene (C), Janssen-Cilag (C), Millenium (C), Onyx (C); Sara Bringhen, Onyx (C), Merck Sharp & Dohme (C); Francesco Di Raimondo, Celgene and Janssen-Cilag (C); Roberto Ria, Celgene (C), Janssen-Cilag (C), Novartis (C), Italfarmaco (C); Pellegrino Musto, Celgene (C); Mario Boccadoro, Celgene (C) and Janssen-Cilag (C); Michele Cavo, Janssen-Cilag (C), Celgene (C), Novartis (C), and Millennium Pharmaceuticals (C).

Honoraria: Sara Bringhen, Celgene (C), Janssen-Cilag (C) and Novartis (C); Alessandra Larocca, Celgene and Janssen-Cilag (C); Francesca Patriarca, MSD (C), Janssen-Cilag (C), Celgene (C), Roche (C); Massimo Offidani, Janssen-Cilag (C) and Celgene (C); Maria Teresa Petrucci, Celgene (C), Janssen-Cilag (C); Pellegrino Musto, Celgene (C), Janssen-Cilag (C);

Research funding: Tommasina Guglielmelli, Celgene (C); Pellegrino Musto, Celgene (C), Janssen-Cilag (C);.Mario Boccadoro, Celgene (C) and Janssen-Cilag (C); Michele Cavo, Janssen-Cilag (C), Celgene (C), Novartis (C).

Acknowledgements
We thank all the patients who participated in this study, the nurses Elena Ponticelli and Diego Elia, the data managers Angela Jiang and Tiziana Marangon, and the editorial assistant Giorgio Schirripa. This work was funded by the Italian Medicines Agency (AIFA). The funder had no role in the design and conduct of the study, the collection, analysis, and interpretation of the data.

References:
1. Palumbo A, Anderson K: Multiple myeloma. N Engl J Med 364: 1046–60, 2011.
2. Howlade N, Noone A, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD,

http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012.
3. Fayers PM, Palumbo A, Hulin C, et al: Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118: 1239–47, 2011.
4. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359: 906–17, 2008.
5. San Miguel JF, Schlag R, Khuageva NK, et al: Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. J Clin Oncol 31: 448-55, 2013.
6. Palumbo A, Bringhen S, Rossi D, et al: Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28: 5101–9, 2010.
7. Ludwig H, Durie BGM, McCarthy P, et al: IMWG consensus on maintenance therapy in multiple myeloma. Blood 119: 3003–15, 2012.
8. Mateos M-V, Oriol A, Martínez-López J, et al: Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11: 934–41; 2010.
9. Durie BGM, Harousseau J-L, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20: 1467–73, 2006.
10. National Cancer Institute: Common Terminology Criteria for Adverse Events, v3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_v3.0.
11. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–81; 1958.
12. Cox D: Regression model and life tables. J R Stat Soc B 34: 187–220, 1972.
13. Greipp PR, San Miguel J, Durie BGM, et al: International staging system for multiple myeloma. J Clin Oncol 23: 3412–20, 2005.
14. Palumbo A, Bringhen S, Caravita T, et al: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367: 825–31, 2006.
15. Palumbo A, Bringhen S, Liberati AM, et al: Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112: 3107–14; 2008.
16. Waage A, Gimsing P, Fayers P, et al: Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116: 1405–12, 2010.
17. Wijermans P, Schaafsma M, Termorshuizen F, et al: Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 28: 3160–6, 2010.
18. Facon T, Mary JY, Hulin C, et al: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370: 1209–18, 2007.
19. Hulin C, Facon T, Rodon P, et al: Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27: 3664–70, 2009.
20. Beksac M, Haznedar R, Firatli-Tuglular T, et al: Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 86: 16–22, 2011.

21. Harousseau J-L, Attal M, Avet-Loiseau H, et al: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28: 4621–9, 2010.
22. Sonneveld P, Schmidt-Wolf IGH, Van der Holt B, et al: Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 30: 2946–55, 2012.
23. Cavallo F, Hardan I, Gay F, et al: Lenalidomide maintenance significantly reduces the risk of progression in newly diagnosed young multiple myeloma patients enrolled in RV-MM-PI-209 trial. Haematologica abstract 1142, 2012.
24. Hoering A, Crowley J, Shaughnessey JD, et al: Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood 114: 1299-1305, 2009.
25. Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al: Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with long survival with longer survival. J Clin Oncol 26: 5775-81, 2008.
26. Gay F, Larocca A, Wijermans P, et al: Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117: 3025–31, 2011.
27. Palumbo A, Hajek R, Delforge M, et al: Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366: 1759-69, 2012.
28. McCarthy PL, Owzar K, Hofmeister CC, et al: Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366: 1770-81, 2012.
29. Attal M, Lauwers-Cances V, Marit G, et al: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1782-91, 2012.
30. Morgan GJ, Gregory WM, Davies FE, et al: The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119: 7–15, 2012.
31. Mateos M-V, Oriol A, Martínez-López J, et al: Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120: 2581–8, 2012.
32. Cavo M, Sonneveld P, Moreau P, et al: Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies. Blood 120: abstract 749, 2012;.
33. Niesvizky R, Flinn IW, Rifkin R, et al: Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study. Blood 118: abstract 478; 2011.
34. Palumbo A, Bringhen S, Ludwig H, et al: Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118: 4519–29, 2011.
35. Bringhen S, Larocca A, Rossi D, et al: Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116: 4745–53, 2010.
36. Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116: 679-86, 2010.
37. Jakubowiak AJ, Dytfeld D, Griffith KA, at al: A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120: 1801-9, 2012.

Table 1. Adverse Events

Events	VMPT-VT Group (N = 250)*	VMP Group (N = 253)*	
	Grade 3 to 4	Grade 3 to 4	P-value

Haematologic events	119 (48%)	104 (41%)	0.13
Neutropenia	96 (38%)	71 (28%)	0.01
Thrombocytopenia	55 (22%)	50 (20%)	0.5
Anaemia	25 (10%)	25 (10%)	
Non-haematologic events	135 (54)	84 (33%)	<0.001
Cardiologic events	28 (11%)	14 (5%)	0.02
Myocardial infarction/Angina	4	5	
Arrhythmia	11	2	
Cardiac failure	7	4	
Other	6	3	
Nervous system disorder	53 (21%)	39 (15%)	0.09
Sensory neuropathy	27 (11%)	13 (5%)	0.02
Neuralgia	9 (4%)	7 (3%)	
Sensory neuropathy and neuralgia	9 (4%)	11 (4%)	
Ictus	2	2	
Confusion	2	0	
Mood depression	0	2	
Other	2	2	
Infections	32 (13%)	23 (9%)	0.18
Pneumonia	14	6	
Neutropenic fever	6	5	
Viral infection	3	1	
Sepsis	4	5	
Other	5	6	
Gastrointestinal events	16 (6%)	21 (8%)	0.42
Diarrhoea	4	7	
Constipation	6	5	
Nausea/Vomiting	2	3	
Other	4	6	
Vascular events	13 (5%)	5 (2%)	0.05
Deep-vein thrombosis	8	5	
Pulmonary embolism	4	0	
Peripheral edema	1	0	
Systemic events	16 (6%)	8 (3%)	0.09
Fatigue	15	5	
Fever	1	3	
Other conditions	27 (11%)	20 (8%)	0.26
Discontinuations due to adverse events	70 (28%)	40 (16%)	0.001

Data are number (%). VMPT-VT,bortezomib, melphalan, prednisone, thalidomide followed by continuous therapy with bortezomib and thalidomide. VMP, bortezomib, melphalan, prednisone * A total of 8 patients, 4 in each study group, could not be evaluated for adverse events because they did not receive a study drug due to withdrawal of consent (3 patients in the VMPT-VT group and 1 in the VMP), progressive disease (1 patient in each group), physician choice (2 patients in the VMP).

FIGURE LEGEND

Figure 1. Randomization and Follow-up of the Study Patients. VMP-VT denotes bortezomib-melphalan–prednisone-thalidomide induction followed by bortezomib-thalidomide maintenance, VMP bortezomib-melphalan–prednisone induction without maintenance.

Figure 2. Survival Outcomes in the Intention-to-Treat Population, According to Study Group. Panel A shows progression-free-survival. Panel B shows time-to-next-therapy. Panel C shows overall survival. Panel D shows overall survival from relapse. HR, hazard ratio; CI, confidence interval; VMP-VT, bortezomib-melphalan–prednisone-thalidomide induction followed by bortezomib-thalidomide maintenance; VMP, bortezomib-melphalan–prednisone induction without maintenance.

Figure 1.




Randomized
(N=511)
Allocated to VMPT-VT (N=254)
Received treatment (N=250)
Did not receive treatment (N=4)
Reasons:
Progressive disease (n=1)
Withdrawal of consent (n=3)
Allocated to VMP (N=257)
Received treatment (N=253)
Did not receive treatment (N=4)
Reasons:
Physician choice (n=2)
Withdrawal of consent (n=1)
Progressive disease (n=1)
Completed treatment (N=163)
Discontinued treatment (N=87)
Reasons:
Adverse events (n=52)
Progressive disease (n=15)
Withdrawal of consent (n=7)
Lost to follow-up (n=0)
Other (n=13)
Completed treatment (N=154)
Discontinued treatment (N=99)
Reasons:
Adverse events (n=43)
Progressive disease (n=30)
Withdrawal of consent (n=16)
Lost to follow-up (n=8)
Other (n=2)
Received maintenance (N=149)
Did not receive maintenance (N=14)
Adverse event (n=5)
Progressive Disease (n=5)
Withdrawal of consent (n=4)
Maintenance completed (N=78)
Discontinued maintenance (N=71)
Progressive Disease (n=50)
Adverse event (n=19)
Withdrawal of consent (n=2)
Relapsed patients (N=133)
Received subsequent therapy (N=105)
Did not receive subsequent therapy (N=28)
Relapsed patients (N=185)
Received subsequent therapy (N=152)
Did not receive subsequent therapy (N=33)

2 A: Progression-free-survival



Patients at Risk

Time	0	12	24	36	48	60	72
VMPT–VT	257	194	121	66	39	12	1
VMP	254	204	153	110	70	24	5

2 B: Time-to-next-therapy



Patients at Risk

Time	0	12	24	36	48	60	72
VMPT–VT	257	199	132	75	46	13	1
VMP	254	205	161	123	78	29	5

2 C: Overall survival



Patients at Risk

Time	0	12	24	36	48	60	72
VMPT–VT	257	221	185	161	120	47	7
VMP	254	215	196	178	129	51	9

2 D: Overall survival from relapse



Patients at Risk

Time	0	12	24	36	48	60
VMPT–VT	180	120	75	34	7	0
VMP	123	81	41	20	5	0

SUPPLEMENTARY APPENDIX

Table 1 (Appendix). Baseline Characteristics of the Patients

Variable	VMPT-VT (N = 254)	VMP (N = 257)
Age		
Median-years	71	71
IQR-years	68-75	68-75
Subgroup		
< 65 years	12 (5%)	6 (2%)
65-74 years	174 (68%)	182 (71%)
≥ 75 years	68 (27%)	69 (27%)
Male sex	130 (51%)	122 (47%)
Serum β_2-microglobulin level		
Median-mg/L	3.8	4
IQR-mg/L	2.7-5.2	3.0-5.6
Subgroup		
≤ 3.5 mg/L	93 (37%)	84 (33%)
> 3.5 mg/L	118 (46%)	125 (49%)
Data missing	43 (17%)	48 (18%)
Albumin level		
Median-g/L	37.9	37.5
IQR-g/L	33.1-41.0	33.7-41.0
Data missing	32 (12.5%)	34 (13%)
International Staging System stage		
I	59 (23%)	56 (22%)
II	100 (39%)	88 (34%)
III	47 (19%)	57 (22%)
Data missing	48 (19%)	56 (22%)
Creatinine clearance (calculated)		
< 30 ml/min	21 (8%)	24 (9%)
30-60 ml/min	147 (58%)	160 (62%)
> 60 ml/min	86 (34%)	73 (28%)
LDH level		
Median-UI/L	277	293
IQR -UI/L	193-355	203-368
Data missing	51 (20%)	36 (14%)
Chromosome abnormalities		
Del 13	101/192 (53%)	86/184 (47%)
t(4;14)	33/192 (17%)	26/184 (14%)
t(11;14)	31/192 (16%)	20/184 (11%)
t(14;16)	9/192 (5%)	6/184 (3%)
Del17	32/192 (17%)	23/184 (13%)
Bortezomib schedule		
Twice-weekly	73 (29%)	66 (26%)
Once-weekly	181 (71%)	191 (74%)

VMPT-VT,bortezomib, melphalan, prednisone, thalidomide followed by continuous therapy with bortezomib and thalidomide. VMP, bortezomib, melphalan, prednisone. IQR, interquartile range

Table 2 (Appendix). Multivariate analysis of variables favourably affecting overall survival

Variable	HR	95% CI	P value
Randomization to VMPT-VT	0.69	0.50-0.94	0.02
Age < 75 years	0.58	0.41-0.83	0.002
Female gender	0.62	0.45-0.86	0.003
ISS 1-2	0.69	0.49-0.98	0.04

HR, hazard ratio; CI, confidence interval; VMPT-VT, bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide; ISS, International Staging System.

Table 3 (Appendix). Cumulative doses and drug-discontinuation according to age

	VMPT-VT		VMP	
	Age < 75 years (N=186)	Age ≥ 75 years (N=68)	Age < 75 years (N=188)	Age ≥ 75 years (N=69)
Total				
Discontinuation due to adverse events – n (%)	46 (25)	24 (35)	29 (15)	11 (16)
Treatment duration - median, months (IQR)	24 (12-36)	11 (4-22)	12 (7-12)	12 (8-12)
Bortezomib dose intensity - % Cumulative dose - median, mg/m^2 (IQR)	81 88.5 (59.4-106.3)	58 63.7 (52.9-93.8)	89 41.6 (22.5-46.8)	80 37.3 (25.7-42.9)
Induction				
Discontinuation due to adverse events – n (%)	31 (17)	20 (29)	29 (15)	11 (16)
Treatment duration - median, months (IQR)	12 (11-12)	11 (4-12)	12 (7-12)	12 (8-12)
Bortezomib dose intensity - % Cumulative dose - median, mg/m^2 (IQR)	89 41.6 (27.9-46.8)	63 29.7 (14.7-42.5)	89 41.6 (22.5-46.8)	80 37.3 (25.7-42.9)
Maintenance				
Discontinuation due to adverse events – n (%)*	15 (12)	4 (14)	-	-
Treatment duration - median, months (IQR)	24 (13-24)	15 (4-24)	-	-
Bortezomib dose intensity - % Cumulative dose - median, mg/m^2 (IQR)	77 48.0 (25.2-62.4)	49 30.5 (7.2-54.7)	-	-

* Rate calculated on 120 patients younger than 75 years and 29 patients older than 75 years who started maintenance; IQR, interquartile range; VMPT-VT, bortezomib, melphalan, prednisone, thalidomide followed by maintenance with bortezomib and thalidomide; VMP, bortezomib, melphalan, prednisone; IQR, interquartile range

FIGURE LEGEND (SUPPLEMENTARY APPENDIX)

Figure 1. Schedule of induction and maintenance treatment. VMP denotes bortezomib-melphalan–prednisone induction without maintenance, VMPT-VT bortezomib-melphalan–prednisone-thalidomide induction followed by bortezomib-thalidomide maintenance.

Figure 1 (Appendix) Treatment schedule